Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in selective immunosuppression

L Adorini1, J C Guéry, S Trembleau

  • 1Roche Milano Ricerche, Italy.

Advances in Pharmacology (San Diego, Calif.)
|January 1, 1995
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective effect of UDCA against IL-11- induced cardiac fibrosis is mediated by TGR5 signalling.

Frontiers in cardiovascular medicine·2024
Same author

Farnesoid X receptor activation by the novel agonist TC-100 (3α, 7α, 11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid) preserves the intestinal barrier integrity and promotes intestinal microbial reshaping in a mouse model of obstructed bile acid flow.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2022
Same author

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

PloS one·2019
Same author

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Journal of endocrinological investigation·2019
Same author

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Journal of endocrinological investigation·2018
Same author

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Biochimica et biophysica acta. Molecular basis of disease·2017
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles